<DOC>
	<DOCNO>NCT00755976</DOCNO>
	<brief_summary>RATIONALE : Sulindac may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , epirubicin , work different way stop growth tumor cell , either kill cell stop divide . Giving sulindac together epirubicin may kill tumor cell . PURPOSE : This phase II trial study well give sulindac together epirubicin work treat patient metastatic malignant melanoma .</brief_summary>
	<brief_title>Sulindac Epirubicin Treating Patients With Metastatic Malignant Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To estimate non-comparative efficacy sulindac epirubicin hydrochloride patient metastatic malignant melanoma . Secondary - To characterize toxicity regimen patient . OUTLINE : This multicenter study . Patients receive oral sulindac 2 hour prior receive epirubicin hydrochloride IV 15 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Previously collect tumor block assess cancer resistance marker IHC . After completion study treatment , patient follow 1 month , every 3 month thereafter .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant melanoma Metastatic disease Tumor block available resistance marker analysis Measurable evaluable disease No active brain metastasis except patient undergone successful complete excision solitary brain metastasis PATIENT CHARACTERISTICS : Karnofsky performance status 80100 % ANC &gt; 1 x 10^9/L Platelet count &gt; 100 x 10^9/L Hemoglobin &gt; 9 g/dL Serum bilirubin normal ( except patient benign congenital hyperbilirubinemia ) Not pregnant nursing Negative pregnancy test Normal cardiac ejection fraction , cardiac wall motion , ECG No active heart disease , include follow : Myocardial infarction within past year Pericarditis Existing hypertension require treatment No active serious medical psychiatric disease No prior concurrent malignancy , basal cell carcinoma skin , carcinoma insitu cervix PRIOR CONCURRENT THERAPY : No prior anthracycline anthracenedionecontaining chemotherapy regimen No prior cardiac radiotherapy No major surgery within past 2 week No participation clinical trial within past 4 week No concurrent anticancer therapy Concurrent bisphosphonates allow patient bony metastasis extraosseous measurable evaluable lesion No concurrent experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage IV melanoma</keyword>
</DOC>